258 related articles for article (PubMed ID: 27404228)
1. Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies.
Servian P; Celma A; Planas J; Placer J; de Torres IM; Morote J
Prostate; 2016 Dec; 76(16):1501-1506. PubMed ID: 27404228
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of proliferative inflammatory atrophy finding in prostatic biopsies.
Servian P; Celma A; Planas J; Placer J; de Torres IM; Olivan M; Morote J
Prostate; 2015 Oct; 75(14):1669-75. PubMed ID: 26184870
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
4. Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.
Ploussard G; Nicolaiew N; Marchand C; Terry S; Allory Y; Vacherot F; Abbou CC; Salomon L; de la Taille A
BJU Int; 2013 May; 111(6):988-96. PubMed ID: 23452046
[TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome is not associated with greater evidences of proliferative inflammatory atrophy and inflammation in patients with suspected prostate cancer.
Russo GI; Cimino S; Giranio G; Regis F; Favilla V; Privitera S; Motta F; Caltabiano R; Stenzl A; Todenhöfer T; Morgia G
Urol Oncol; 2018 May; 36(5):240.e21-240.e26. PubMed ID: 29429896
[TBL] [Abstract][Full Text] [Related]
6. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
7. Significance of focal proliferative atrophy lesions in prostate biopsy cores that test negative for prostate carcinoma.
Asimakopoulos AD; Miano R; Mauriello A; Costantini S; Pasqualetti P; Liberati E; Finazzi Agrò E; Germani S; Virgili G; Vespasiani G
Urol Oncol; 2011; 29(6):690-7. PubMed ID: 20451420
[TBL] [Abstract][Full Text] [Related]
8. Simple Risk Stratification to Detect Prostate Cancer with High Gleason Score in Repeat Biopsies in a Population Screening Follow-up Study.
Kitagawa Y; Urata S; Mizokami A; Nakashima K; Koshida K; Nakashima T; Miyazaki K; Namiki M
Anticancer Res; 2015 Sep; 35(9):5031-6. PubMed ID: 26254404
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study.
Morote J; Celma A; Planas J; Placer J; Ferrer R; de Torres I; Pacciuci R; Olivan M
Actas Urol Esp; 2016; 40(6):378-85. PubMed ID: 26923032
[TBL] [Abstract][Full Text] [Related]
10. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
Elshafei A; Li YH; Hatem A; Moussa AS; Ethan V; Krishnan N; Li J; Jones JS
Prostate; 2013 Dec; 73(16):1796-802. PubMed ID: 24038200
[TBL] [Abstract][Full Text] [Related]
11. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
12. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
Djavan B; Zlotta AR; Remzi M; Ghawidel K; Bursa B; Hruby S; Wolfram R; Schulman CC; Marberger M
Urology; 1999 Nov; 54(5):846-52. PubMed ID: 10565745
[TBL] [Abstract][Full Text] [Related]
13. Prediction of clinically significant prostate cancer after negative prostate biopsy: The current value of microscopic findings.
Morote J; Schwartzman I; Borque A; Esteban LM; Celma A; Roche S; de Torres IM; Mast R; Semidey ME; Regis L; Santamaría A; Planas J; Trilla E
Urol Oncol; 2021 Jul; 39(7):432.e11-432.e19. PubMed ID: 33160846
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of proliferative inflammatory atrophy in prostate biopsy.
Celma A; Servián P; Planas J; Placer J; Quilez MT; Arbós MA; de Torres I; Morote J
Actas Urol Esp; 2014 Mar; 38(2):122-6. PubMed ID: 24129226
[TBL] [Abstract][Full Text] [Related]
15. High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy.
Mabjeesh NJ; Lidawi G; Chen J; German L; Matzkin H
BJU Int; 2012 Oct; 110(7):993-7. PubMed ID: 22394668
[TBL] [Abstract][Full Text] [Related]
16. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
Schoenfield L; Jones JS; Zippe CD; Reuther AM; Klein E; Zhou M; Magi-Galluzzi C
BJU Int; 2007 Apr; 99(4):770-4. PubMed ID: 17233800
[TBL] [Abstract][Full Text] [Related]
17. Predictors of prostate cancer on extended biopsy in patients with high-grade prostatic intraepithelial neoplasia: a multivariate analysis model.
Abdel-Khalek M; El-Baz M; Ibrahiem el-H
BJU Int; 2004 Sep; 94(4):528-33. PubMed ID: 15329106
[TBL] [Abstract][Full Text] [Related]
18. Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer?
Kim SJ; Jeong TY; Yoo DS; Park J; Cho S; Kang SH; Lee SH; Jeon SH; Lee TY; Park SY
Yonsei Med J; 2015 Nov; 56(6):1492-6. PubMed ID: 26446628
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
[TBL] [Abstract][Full Text] [Related]
20. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
